Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
80,235,145
-
Total 13F shares
-
57,350,132
-
Share change
-
-1,082,917
-
Total reported value
-
$797,188,696
-
Put/Call ratio
-
13%
-
Price per share
-
$13.90
-
Number of holders
-
120
-
Value change
-
-$18,249,775
-
Number of buys
-
60
-
Number of sells
-
53
Institutional Holders of Kymera Therapeutics, Inc. - Common Stock (KYMR) as of Q3 2023
As of 30 Sep 2023,
Kymera Therapeutics, Inc. - Common Stock (KYMR) was held by
120 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
57,350,132 shares.
The largest 10 holders included
Atlas Venture Life Science Advisors, LLC, PRICE T ROWE ASSOCIATES INC /MD/, WELLINGTON MANAGEMENT GROUP LLP, BAKER BROS. ADVISORS LP, BVF INC/IL, VANGUARD GROUP INC, Avoro Capital Advisors LLC, BlackRock Inc., STATE STREET CORP, and Redmile Group, LLC.
This page lists
120
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.